[HTML][HTML] NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
W Wang, AK Erbe, JA Hank, ZS Morris… - Frontiers in …, 2015 - frontiersin.org
Natural killer (NK) cells play a major role in cancer immunotherapies that involve tumor-
antigen targeting by monoclonal antibodies (mAbs). NK cells express a variety of activating …
antigen targeting by monoclonal antibodies (mAbs). NK cells express a variety of activating …
[HTML][HTML] Antitumor activity of hu14. 18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study
S Shusterman, WB London, SD Gillies… - Journal of Clinical …, 2010 - ncbi.nlm.nih.gov
Purpose The hu14. 18-IL2 fusion protein consists of interleukin-2 molecularly linked to a
humanized monoclonal antibody that recognizes the GD2 disialoganglioside expressed on …
humanized monoclonal antibody that recognizes the GD2 disialoganglioside expressed on …
Long-term follow-up of a phase III study of ch14. 18 (dinutuximab)+ cytokine immunotherapy in children with high-risk neuroblastoma: COG study ANBL0032
Purpose: Previously our randomized phase III trial demonstrated that immunotherapy
including dinutuximab, a chimeric anti-GD2 mAb, GM-CSF, and IL2 improved survival for …
including dinutuximab, a chimeric anti-GD2 mAb, GM-CSF, and IL2 improved survival for …
Irinotecan, temozolomide, and dinutuximab with GM-CSF in children with refractory or relapsed neuroblastoma: a report from the Children's Oncology Group
PURPOSE The combination of irinotecan, temozolomide, dintuximab, and granulocyte-
macrophage colony-stimulating factor (I/T/DIN/GM-CSF) demonstrated activity in patients …
macrophage colony-stimulating factor (I/T/DIN/GM-CSF) demonstrated activity in patients …
Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14. 18-IL2 immunotherapy
DC Delgado, JA Hank, J Kolesar, D Lorentzen, J Gan… - Cancer research, 2010 - AACR
Response to immunocytokine (IC) therapy is dependent on natural killer cells in murine
neuroblastoma (NBL) models. Furthermore, killer immunoglobulin-like receptor (KIR)/KIR …
neuroblastoma (NBL) models. Furthermore, killer immunoglobulin-like receptor (KIR)/KIR …
Phase I study of ch14. 18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow …
AL Gilman, MF Ozkaynak, KK Matthay… - Journal of Clinical …, 2009 - ascopubs.org
Purpose Recurrence of high-risk neuroblastoma is common despite multimodality therapy.
ch14. 18, a chimeric human/murine anti-GD2 antibody, lyses neuroblastoma cells. This …
ch14. 18, a chimeric human/murine anti-GD2 antibody, lyses neuroblastoma cells. This …
A phase I/IB trial of murine monoclonal anti‐GD2 antibody 14. G2a plus interleukin‐2 in children with refractory neuroblastoma: a report of the Children's Cancer …
JD Frost, JA Hank, GH Reaman… - … Journal of the …, 1997 - Wiley Online Library
BACKGROUND The murine monoclonal antibody (MoAb) 14. G2a recognizes GD2, a
disialoganglioside expressed in tumors of neuroectodermal origin, and facilitates antibody …
disialoganglioside expressed in tumors of neuroectodermal origin, and facilitates antibody …
A phase I clinical trial of the hu14. 18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's …
KL Osenga, JA Hank, MR Albertini, J Gan… - Clinical cancer …, 2006 - AACR
Purpose: Evaluate the clinical safety, toxicity, immune activation/modulation, and maximal
tolerated dose of hu14. 18-IL2 (EMD 273063) in pediatric patients with recurrent/refractory …
tolerated dose of hu14. 18-IL2 (EMD 273063) in pediatric patients with recurrent/refractory …
Augmentation of Antibody Dependent Cell Mediated Cytotoxicity following in Vivo Therapy with Recombinant Interleukin 2
JA Hank, RR Robinson, J Surfus, BM Mueller… - Cancer research, 1990 - AACR
Monoclonal antibodies (mAB) with tumor specificity are able to enhance the immunological
specificity of interleukin 2 (IL-2)-activated lymphokine activated killer (LAK) cells. Antibodies …
specificity of interleukin 2 (IL-2)-activated lymphokine activated killer (LAK) cells. Antibodies …
[HTML][HTML] Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14. 18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma
F Navid, PM Sondel, R Barfield, BL Shulkin… - Journal of clinical …, 2014 - ncbi.nlm.nih.gov
Purpose The addition of immunotherapy, including a combination of anti-GD2 monoclonal
antibody (mAb), ch14. 18, and cytokines, improves outcome for patients with high-risk …
antibody (mAb), ch14. 18, and cytokines, improves outcome for patients with high-risk …